The National Institutes of Health (NIH) is offering this grant through its HEAL Initiative to advance scientific solutions for the national opioid crisis by enhancing pain management. This grant is for developing innovative quantitative imaging and other relevant biomarkers of myofascial tissues for clinical pain management. The two-phase R61/R33 mechanism requires clinical trials. The R61 phase supports developing measures to differentiate myofascial pain stages and initial team building. The R33 phase then funds assessing these measures’ ability to monitor responses and predict outcomes of pain management regimens in longitudinal interventional studies. This initiative seeks to improve treatment and prevention of opioid misuse by bolstering research in pain.
Opportunity ID: 336570
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AT-22-003 |
| Funding Opportunity Title: | HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 16, 2021 |
| Last Updated Date: | Nov 16, 2021 |
| Original Closing Date for Applications: | Feb 11, 2022 |
| Current Closing Date for Applications: | Feb 11, 2022 |
| Archive Date: | Mar 19, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Special district governments County governments Small businesses Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Private institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The National Institutes of Health (NIH) intends to support the development of innovative quantitative imaging and other relevant biomarkers of myofascial tissues for pain management involving research participants using a two-phase grant funding mechanism. This effort is part of NIHs Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. This funding opportunity announcement (FOA) seeks research applications to develop quantitative imaging biomarkers of myofascial tissues and assess their abilities to monitor responses and/or predict outcomes of a variety of pain management regimens. Candidates for the quantitative imaging biomarkers may include objective measures based on minimally invasive imaging technologies, electrophysiological recordings, integration of multiparametric imaging and electrophysiology approaches, or their integration with other markers (e.g., immune factors, genomic markers, physiological factors, etc.) through multiscale modeling or machine learning analysis. The first phase, funded by the R61, will provide funding for up to three years to develop quantitative measures that can differentiate myofascial tissue abnormalities in healthy versus latent, versus active myofascial pain stages using cross-sectional correlations with clinical signs/symptoms. In addition, the R61 phase should include team building and planning activities for the R33 phase. The second phase, funded under the R33, will provide up to two years of support to assess the abilities of the quantitative measures developed in the R61 phase to monitor responses and/or predict outcomes in response to specified therapies to relieve myofascial pain in longitudinal interventional studies. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AT-22-003.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 336570 Full Announcement-RFA-AT-22-003 -> RFA-AT-22-003-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00270485 | Jan 11, 2022 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270597 | Jan 11, 2022 | Feb 11, 2022 | View |
Package 1
Mandatory forms
336570 RR_SF424_2_0-2.0.pdf
336570 PHS398_CoverPageSupplement_5_0-5.0.pdf
336570 RR_OtherProjectInfo_1_4-1.4.pdf
336570 PerformanceSite_2_0-2.0.pdf
336570 RR_KeyPersonExpanded_2_0-2.0.pdf
336570 RR_Budget_1_4-1.4.pdf
336570 PHS398_ResearchPlan_4_0-4.0.pdf
336570 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
336570 RR_SubawardBudget30_1_4-1.4.pdf
336570 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
336570 RR_SF424_5_0-5.0.pdf
336570 PHS398_CoverPageSupplement_5_0-5.0.pdf
336570 RR_OtherProjectInfo_1_4-1.4.pdf
336570 PerformanceSite_4_0-4.0.pdf
336570 RR_KeyPersonExpanded_4_0-4.0.pdf
336570 RR_Budget_3_0-3.0.pdf
336570 PHS398_ResearchPlan_4_0-4.0.pdf
336570 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
336570 RR_SubawardBudget30_3_0-3.0.pdf
336570 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
